TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
OCS was responsible for 5,139 U.S. transplants in 2025, up from 3,735 in 2024
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceAlmost 50% of incremental investment in 2026 is driven by three elements that are transitory by nature
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceUpcoming registry publication will demonstrate unequivocal statistical superiority in the most important outcomes after liver transplantation
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceTransMedics has huge opportunities ahead but also a few challenges and moving dynamics, which were factored into realistic guidance
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics achieved its best operational performance to date despite external challenges earlier in the year designed to distract and disrupt sustained growth
80% confidenceTransMedics achieved our best operational performance to date with these results achieved despite external challenges earlier in the year that were designed to distract and disrupt our sustained and transformational growth
80% confidenceOCS Heart comprised 18% of heart transplants in 2025, up from 17% in 2024
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics is just getting started and we have our sights focused on new peaks
80% confidenceTransMedics is laser-focused on ensuring successful execution of 2026 initiatives
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue
80% confidenceThe makers of that styrofoam box is refusing to randomize their technology to ours in ENHANCE Part B
80% confidenceTransMedics has huge opportunities ahead but also faces a few challenges and moving dynamics, which have been factored into guidance
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceU.S. transplant revenue grew approximately 11% sequentially to $155 million, while OUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics delivered an operating profit of approximately $21.3 million in Q4, representing approximately 13.2% of total revenue for fourth quarter while making substantial investments to fuel growth
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceNOP Connect 2.0 showing efficiency in management and billing, though these are early days
80% confidenceLiver market share gains represent pure TransMedics execution excellence
80% confidenceCompetitor in ENHANCE Part B trial (makers of styrofoam box) is refusing to randomize their technology against TransMedics
80% confidence